Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Q3 earnings season begins in earnest this week. Wells Fargo, Goldman Sachs, and Citigroup all report Monday. UnitedHealth Group prints the same day, a closely watched result given Medicare Advantage penetration hit a record 51.14% in June 2026, covering 36.1 million beneficiaries, according to ORTEX Alt Data. PepsiCo kicked things off Thursday, with Delta Air Lines following. Results from these names will set the early tone for the season. S&P 500 earnings are forecast to rise around 27% against a backdrop of index highs and elevated long-term borrowing costs.
Options flow is sharply divided. Union Pacific, CSX, and Parker-Hannifin each posted 100% positive options flow over the past seven days ahead of their earnings calls. Meanwhile, chip names drew the heaviest put volume. Micron, Advanced Micro Devices, and NVIDIA absorbed significant bearish bets. South Korean tech stocks fell more than 5% this week on AI-linked weakness on Wall Street, reinforcing the cautious posture in semiconductors. Citigroup compounded the pain with broad target cuts on Norfolk Southern, UPS, and defence names including General Dynamics.
European defence stocks gained after Ukraine ratified a $105 billion EU loan deal. French debt came under fresh selling pressure ahead of elections, raising broader eurozone concerns. In a separate development, Japan's machine tool orders surged 64.7% year-on-year in August 2026, the sharpest rise this cycle, according to ORTEX Alt Data. Foreign orders rose 64.8%, with gains spread across all tracked regions, a sign of broad capital-goods demand rather than a single large order.
Uber COO Andrew MacDonald bought $5.3 million in open-market shares last month, no pre-arranged plan attached. Medical device firm MMED saw short interest jump to 91% of free float, up from 74.5% a week earlier. Talen Energy short interest doubled to 11.9%.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
